CA2735214C - Radiolabeled annexins for diagnostic imaging of cell death - Google Patents

Radiolabeled annexins for diagnostic imaging of cell death Download PDF

Info

Publication number
CA2735214C
CA2735214C CA2735214A CA2735214A CA2735214C CA 2735214 C CA2735214 C CA 2735214C CA 2735214 A CA2735214 A CA 2735214A CA 2735214 A CA2735214 A CA 2735214A CA 2735214 C CA2735214 C CA 2735214C
Authority
CA
Canada
Prior art keywords
annexin
subject
radiolabeled
histidine residues
radionuclide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2735214A
Other languages
English (en)
French (fr)
Other versions
CA2735214A1 (en
Inventor
Christiaan Peter Maria Reutelingsperger
Peter Jozef Jacobus Moonen
Original Assignee
MosaMedix BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MosaMedix BV filed Critical MosaMedix BV
Publication of CA2735214A1 publication Critical patent/CA2735214A1/en
Application granted granted Critical
Publication of CA2735214C publication Critical patent/CA2735214C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2735214A 2008-08-26 2009-08-26 Radiolabeled annexins for diagnostic imaging of cell death Expired - Fee Related CA2735214C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08162959 2008-08-26
EP08162959.4 2008-08-26
PCT/NL2009/050513 WO2010024673A1 (en) 2008-08-26 2009-08-26 Radiolabeled annexins

Publications (2)

Publication Number Publication Date
CA2735214A1 CA2735214A1 (en) 2010-03-04
CA2735214C true CA2735214C (en) 2020-02-18

Family

ID=40219416

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2735214A Expired - Fee Related CA2735214C (en) 2008-08-26 2009-08-26 Radiolabeled annexins for diagnostic imaging of cell death

Country Status (9)

Country Link
US (1) US8747808B2 (enExample)
EP (1) EP2328622B1 (enExample)
JP (1) JP5801196B2 (enExample)
AU (1) AU2009286244B2 (enExample)
CA (1) CA2735214C (enExample)
DK (1) DK2328622T3 (enExample)
ES (1) ES2530228T3 (enExample)
NZ (1) NZ591388A (enExample)
WO (1) WO2010024673A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0914446D0 (en) * 2009-08-18 2009-09-30 King S College London Bioconjugates and their uses in imaging

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1265572A (zh) 1997-04-30 2000-09-06 莱兰斯坦福初级大学评议会 活体内造影细胞死亡的方法
US6323313B1 (en) * 1999-06-01 2001-11-27 The University Of Washington Annexin derivative with endogenous chelation sites
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
AU2003903504A0 (en) * 2003-07-08 2003-07-24 Johnson, Daniel Improvements in sensor chips
CA2559167A1 (en) 2004-03-11 2005-09-22 Alavita, Inc. Modified annexin proteins and methods for preventing thrombosis
US7511016B2 (en) 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
JP2006316004A (ja) 2005-05-13 2006-11-24 Kanazawa Univ アポトーシスのイメージング剤
NZ569078A (en) 2005-12-12 2012-01-12 Mosamedix Bv Annexin derivatives suitable for pretargeting in therapy and diagnosis

Also Published As

Publication number Publication date
EP2328622A1 (en) 2011-06-08
US20110251486A1 (en) 2011-10-13
WO2010024673A1 (en) 2010-03-04
JP5801196B2 (ja) 2015-10-28
EP2328622B1 (en) 2014-12-17
CA2735214A1 (en) 2010-03-04
AU2009286244B2 (en) 2014-08-14
AU2009286244A1 (en) 2010-03-04
ES2530228T3 (es) 2015-02-27
DK2328622T3 (en) 2015-02-02
NZ591388A (en) 2012-06-29
US8747808B2 (en) 2014-06-10
JP2012501322A (ja) 2012-01-19

Similar Documents

Publication Publication Date Title
TWI837077B (zh) 藉由IgG結合肽之部位特異性RI標識抗體
TWI891668B (zh) 具有經ｒｉ標定之人類化抗體的複合體、放射性醫藥
TW200306984A (en) Annexin derivatives with endogenous chelation sites
Rudd et al. Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor
US20240132546A1 (en) Charge modified designed repeat domains and their use
CN107308466B (zh) 具有肿瘤血管靶向性的多肽、分子探针及其制备方法和应用
US5821330A (en) Peptide having inflammation affinity and radioactive diagnostic containing the same
WO2023184839A1 (zh) 一种新型靶向肿瘤PD-L1的探针 99mTc标记亲合体的制备
US8747808B2 (en) Radiolabeled annexins
JP7864129B2 (ja) 新規ｈｅｒ２結合ポリペプチド
US20240189461A1 (en) Humanised antibodies labelled with radionuclides that emit beta-rays
Clark et al. Site-specific 32P-labeling of cytokines, monoclonal antibodies, and other protein substrates for quantitative assays and therapeutic application
KR20230174238A (ko) 방사성 항종양제
KR20230163487A (ko) 항egfr 항체의 방사성 복합체 및 방사성 의약
EA052452B1 (ru) Ri-меченное гуманизированное антитело
TW202233247A (zh) 抗ｈｅｒ２抗體之放射性複合體及放射性醫藥
HK1259612A1 (en) SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140724

MKLA Lapsed

Effective date: 20210826